FOLFIRI + bevacizumab

DRUG3 trials

Sponsors

Pfizer, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Sun Yat-sen University

Conditions

Colorectal Cancer MetastaticColorectal NeoplasmsMicrosatellite Stable (MSS) Colorectal Cancer (CRC)

Phase 2

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)

CompletedNCT01640444

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Colorectal Cancer Metastatic

Start: 2012-07-31End: 2018-11-30Updated: 2019-04-11

Phase 3

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

CompletedNCT00101686

PfizerColorectal Neoplasms

Start: 2003-02-28End: 2008-10-31Updated: 2010-01-12

FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

Not yet recruitingNCT07729605

Sun Yat-sen UniversityColorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)

Start: 2026-07-30End: 2029-07-30Target: 270Updated: 2026-07-27

Related Papers

Associations of blood RNA biomarkers and circulating tumour cells in patients with previously untreated metastatic colorectal cancer.

2025-04-21

Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials.

2023-02-214 citations

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.

2020-03-0628 citations